Status:
COMPLETED
Adalimumab Biosimilar in Clinical Practice
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Conditions:
Psoriasis
Eligibility:
All Genders
2-90 years
Brief Summary
This is an observational, retrospective, multicenter, and descriptive study of patients treated with adalimumab biosimilar for psoriasis, according to clinical practice. Existing data will be collect...
Detailed Description
Adalimumab is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic treatment. There are currently several biosimilar drugs (Amge...
Eligibility Criteria
Inclusion
- Patients of both sexes who have received treatment with adalimumab and who have signed an informed consent.
Exclusion
- Refusal to participate.
- Any other cause of exclusion based on clinical criteria and the technical data sheet of the drug.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2021
Estimated Enrollment :
604 Patients enrolled
Trial Details
Trial ID
NCT04808739
Start Date
June 1 2020
End Date
February 28 2021
Last Update
March 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08041